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Summary 
We have created several transgenic mouse strains that bear the human 3` light chain gene driven 
by its own promoter and a mouse immunoglobulin heavy chain enhancer. The transgene is expressed 
in many tissues, with particularly high levels of expression in the bone marrow, thymus, spleen, 
and lymph nodes. One of these transgenic lines, B-less, displays a dramatic phenotype characterized 
by an acute susceptibility to bacterial and viral infections. Analysis of this strain shows it to 
be profoundly deficient in both immature (pre-B) and mature B cells, as well as in circulating 
immunoglobulin. The pre-B and B cell defects are cell autonomous, as judged by cell culture 
and bone marrow graft chimeras. Despite this B cell deficiency, the T cell lineage appears grossly 
normal as assessed by flow cytometric analysis and by its response to mitogen stimulation. Since 
an independently derived transgenic strain bearing the same human 3` construct displays a partial 
B-less phenotype, it is likely that the B lineage deficiency is due to a dominant effect of transgene 
expression rather than to the insertional perturbation of an endogenous mouse gene. It is interesting 
that the deficiency phenotype is fully expressed in the FVB/N genetic background, but is suppressed 
in Fz hybrids formed between the FVB/N  and C57BL/6  inbred strains.  Evidently, there are 
one or more dominant genetic suppressors  of B-less in the C57BL/6  genome. 
I  g genes undergo rearrangement in a precisely ordered fashion 
in which recombination of H  chain gene segments pre- 
cedes that of L chains, and recombination of K chain gene 
segments precedes that of 3` (1). The mechanism responsible 
for this ordered rearrangement is not known, but is thought 
to be related to  transcriptional  controls in which cryptic 
promoters close to the separate germ line gene segments be- 
come activated in an ordered fashion (2).  This activation is 
thought to be necessary for Ig gene recombination and to 
be governed by the rules of allelic exclusion, a process by which 
only one H  chain gene can functionally recombine in each 
B cell, and by the related rules of isotype exclusion, by which 
only one L chain gene can rearrange functionally in each B 
cell. The available data from Ig transgenic mice suggest that 
the presence of functional Ig transgenes in developing B cells 
results in allelic and isotypic exclusion of the corresponding 
endogenous Ig alleles. H chain transgenes inhibit rearrange- 
ment of endogenous H chain genes, and L chain transgenes 
inhibit rearrangement of endogenous L chain genes (3). Fur- 
ther, it is the membrane-bound form of the Ig H chain that 
is required to exclude the expression of endogenous alleles, 
and not the secreted version of the H  chain (4,  5). 
As might be expected, mice bearing Ig H or L chain trans- 
genes have significant perturbations of B cell populations (6, 
7). For example, L chain transgene expression appears to re- 
sult in the reduction of early pre-B cells, suggesting that L 
chain transgenes may interfere with very early stages of B 
cell development (8).  Although a slight impairment of the 
B cell response to bacterial antigens has been observed (9), 
no dramatic immunodeficiency has been reported for any of 
these mice (3).  It is therefore likely that these exclusionary 
rules are sufficiently "leaky" to permit the escape of sufficient 
numbers of B cells,  so as to preserve a functional immune 
response in such animals. 
Our experiments were designed to test further features of 
these exclusionary rules, and to explore the transcriptional 
controls that govern the expression of 3` L chain genes. Ac- 
cordingly, we prepared a fusion transgene consisting of a rear- 
ranged human 3, L chain gene artificially activated by an Ig 
H chain enhancer. Several transgenic animals bearing this con- 
struct were derived and one of these displayed a profound 
immunodeficiency  and sensitivity to infectious disease. Since 
immunodeficient mice have proven to be valuable experimental 
models for elucidating the roles of specific cell types in the 
immune response, we have characterized this line and specu- 
lated regarding the molecular pathogenesis of this defect. Sev- 
eral B cell deficiencies have been described in mutant mice. 
However, unlike our example, none provides a  complete, 
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11). For example, an interesting transgenic mouse expressing 
the interferon response factor 1 (IRF-1) t transgene is also se- 
verely deficient  in  mature  B  cells,  but  retains  significant 
numbers  of bone marrow B cell precursors (12).  A  second 
immunodeficient transgenic mouse has been derived by tar- 
geted disruption  of the membrane exon of the Ig g  chain 
gene (13). These animals, though clearly B cell deficient, ap- 
pear to have normal numbers of bone marrow pre-B cells. 
By contrast,  the B-less  strain reported herein is profoundly 
deficient in B  cells of the earliest  identifiable  stages. 
Materials  and Methods 
Transgenic Mice.  The complete DNA sequence of the rearranged 
human X gene from the U266 cell line is available in the EMBL 
Data Library under the accession number X51754. Detailed struc- 
tural information on this gene was presented previously (14). The 
human X clone consists of an 8.5-kb EcoKI to HindlII fragment, 
containing the VX pseudogene, VX1, as well as the active U266X 
gene rearranged with the Xz constant region gene. To prepare the 
X plasmid,  we inserted the 976-bp XbaI fragment containing the 
mouse Ig H chain enhancer into the HindlII site downstream of 
the X gene by blunt end ligation as shown in Fig.  1. The 9.5-kb 
fragment containing the U266X gene, and the fragment containing 
the Eg (the murine # H chain enhancer) were isolated after EcoRI 
digestion. DNA fragments for microinjection were excised from 
the plasmids  and purified by electroelution after agarose gel elec- 
trophoresis.  The fragments were injected into fertilized oocytes de- 
rived from the FVB/N  x  CD-1 mice (EG) or FVB/N (EH, EO, 
ET, and EZ) as described by Muller et al. (15). FVB/N mice are 
albino (c), agnuti (A), H-2q, and have the b alleles of Lyt-l-3. All 
transgenics are maintained by back-crossing male hemizygotes with 
+/+  FVB/N females. The EG strain (referred to as B-less in this 
text) has currently been back-crossed  with FVB/N for over ten 
generations. This strain has been formally designated as Tg(O; HSA, 
IGL)ILED and is registered at the Jackson Laboratory, Bar Harbor, 
ME.  Unless otherwise specified,  all experiments with the B-less 
animals involve EG/+  hemizygous mice and  +/+  wild-type lit- 
termates between four and ten wk of age. EG/EG homozygotes 
seldom live beyond weaning, and offspring raised by B-less mothers 
are generally unhealthy. 
The Eg-c-myc transgenic strain,  EB, contains the human c-myc 
gene with the mouse Ig H chain enhancer inserted into the first 
c-myc intron (16). 
Cell Lines and Culture.  The X/Eg-c-myc cell line, EG/EB10298, 
is one of four such cell lines isolated from B cell lymphomas that 
arose in mice bearing both transgenes.  This cell line was originally 
cultured from the tumor on bone marrow feeder layers (17), and 
later was weaned from the feeder to grow in KPMI supplemented 
with  10%  FCS.  Ableson  murine  leukemia  virus-(A-MuLV)- 
transformed lines were derived from 14-17 d postcoitum (dpc) fetal 
liver cells, as described for bone marrow cells by Kosenberg and 
Baltimore (18). 
DNA and RNA Analysis.  DNA extraction and blot analyses 
1 Abbreviations used in this  paper: AEC, 3-amino-9-ethylcarbazole;  A-MuLV, 
Ableson murine leukemia  virus; GAR-IG, goat anti-rat lg; GAH-IG, goat 
anti-hamster lg; HR.P, horseradish peroxidase; IRF-1, interferon response 
factor 1; SPF, specific  pathogen-free;  XLA, X-linked agammaglobulinemia. 
were carried out essentially as described by Maniatis et al. (19) using 
the 1.0-kb  BamHI fragment containing the U266X constant re- 
gion as a probe (see Fig. 1 A). RNA was extracted by disrupting 
cells and tissues in a solution of 4 M guanidine isothiocyanate plus 
0.1 M 2-ME and centrifugation through CsC1 (20). RNase pro- 
tection analyses were performed essentially as in Melton et al. (21). 
The probe used for RNA analyses is a uniformly labeled  RNA 
complementary to the U266X V  region, and it protects a 344- 
nucleotide fragment (14). Solution hybridizations were performed 
in the presence of 80%  formamide at 50~  for 4-12 h  and the 
protected fragments  were analyzed on  5%  acrylamide/urea se- 
quencing gels. 
The rearrangement status of the Ig genes in the A-MuLV trans- 
formed cell lines was determined by Southern blotting genomic 
DNA from the cells after restriction digestion with BamHI and 
EcoRI. The blots were sequentially probed with random hexamer- 
labeled  DNA  fragments  containing J.,  Ca,  and  U266  Vx  se- 
quences. 
Protein Analyses.  200/~1 of blood was removed via the retro- 
orbital plexus of anesthetized mice for preparation of serum (and 
nucleated cells for DNA analysis). The concentrations of mouse 
Ig and human X were determined by sandwich immunosorbant 
assay (22). Mouse sera or detergent extracts from tumor cell lines 
and A-MuLV-transformed cell lines were adsorbed to microtiter assay 
plates with either goat anti-mouse Ig or goat anti-human X. The 
same antibodies,  conjugated with alkaline phosphatase,  were then 
bound to the adsorbed proteins for subsequent development and 
colorimetric determinations. 
Flow Cytometry.  Single cell suspensions prepared from lymphoid 
organs  were  either  directly  or  indirectly  stained  with  FITC- 
conjugated antibodies. The antibodies used were: FITC-conjugated 
mouse anti-human X (free and bound, Nordic Laboratories, Capis- 
trano Beach,  CA);  FITC-conjugated monoclonal anti-mouse  K 
(MRCox20; Bioproducts for Science, Inc., Indianapolis, IN); FITC- 
conjugated monospecific goat anti-mouse #  H  chain (Southern 
Biotechnology Associates, Inc., Birmingham, AL); monoclonal rat 
anti-mouse B220 (Ly-5) (6B2, [23, 24]); monoclonal rat anti-mouse 
Sca-I (Ly-6A.2, a gift from Irving Weissman,  Stanford University, 
Stanford, CA [25]);  hamster anti-mouse T3 (clone 2Cll,  [26]); 
FITC-conjugated rat anti-mouse L3T4 (CD4) and Lyt2 (CD8) 
(Becton Dickinson & Co., Mountain View, CA). Unconjugated 
rat mAbs and hamster antibodies were labeled  with FITC-con- 
jugated goat anti-rat Ig or goat anti-hamster antisera (Kirkegaard 
and Perry Laboratories  Inc., Gaithersburg, MD). The labeled cells 
were analyzed on a Cytofluorograf  IIS (Ortho Diagnostic Systems 
Inc., Westwood, MA). 
Immunokistochemical Analysis.  Immunohistochemical analysis 
was performed with 24-g sections cut from OCT-(Miles Laborato- 
ties, Inc., Elkhart, IN) embedded frozen spleens. Sections were fixed 
in acetone and blocked with normal goat serum. Hybridoma su- 
pernatants 6B2 (anti-B220 [LyS]) or M5/49 (anti-Thy-l.1) were ap- 
plied to the sections followed by a second biotinylated anti-rat an- 
tibody (Kirkegaard and Perry Laboratories, Inc.). The stained regions 
were visualized with the Vectastain ABC kit (Vector Laboratories, 
Inc., Burlingame,  CA), which uses avidin/biotin-conjugated horse- 
radish  peroxidase  (HRP),  and 3-amino-9-ethylcarbazole (AEC). 
After development, slides were quenched in 4% formaldehyde. Sec- 
tions  were  counterstained  with  Lerner-1  hematoxylin  (Lerner 
Laboratories,  Pittsburgh, PA), and mounted with Glycergel (Dako 
Corp.,  Carpinteria,  CA). 
Bone Marrow Transplantation.  For bone marrow transplantation, 
recipient mice were lethally irradiated in a GammaceU 40 137Cs 
source (Atomic Energy of Canada, Ltd.). Mice received a split dose 
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mice were injected via the tail vein with 0.2 ml of a suspension 
containing  107 bone marrow cells/ml (27). To facilitate detection 
of wild-type bone marrow, some experiments used marrow from 
the TG.XA transgenic mouse strain (referred to as wt*), an other- 
wise wild-type FVB/N mouse bearing an easily  detected lacZ trans- 
gene  (a gift of Radek  Skoda). 
Mitogen Stimulation Assays.  Mitogen stimulation  assays were 
performed as described in Mishell and Shiigi (28). Single-cell spleno- 
cyte suspensions  were prepared and samples  were transferred to wells 
of microtiter  plates containing  LPS, Con A, or control medium 
and incubated for 68 h. Cultures were pulsed with [3H]thymidine 
(New England Nuclear, Boston,  MA) for 6 h and 3H uptake was 
determined. 
Results and Discussion 
Widespread Expression of  Human A Fusion Gene in Transgenic 
Mile  In the course of studies of Ig gene expression, we gener- 
ated five strains  of transgenic  mice that  express the ~, con- 
struct shown in Fig.  1 A. This construct contains an intact 
human ~, L chain gene and the intronic enhancer (E#) from 
the mouse Ig H  chain  gene.  Such a construct  might  have 
been expected to be expressed specifically  in lymphoid and 
hematopoietic tissues.  However, while the highest levels of 
human k mKNA expression are indeed found in these tissues 
(Fig.  1 B) (bone marrow, thymus, and spleen; note that the 
breast  tissue preparation  includes  lymph  node),  transgene 
mRNA is detectable to an appreciable extent  in all  tissues 
tested (including  liver,  visible on a longer exposure).  Since 
human  X protein  can be detected in  the  serum  and urine, 
as well as within lymphoid cells of transgenic mice (29, and 
see below),  we conclude that  this  mRNA  is  functional. 
The unanticipated ectopic transgene expression we observe 
is unlikely to be due to lymphoid cells that are fortuitously 
present in nonlymphoid tissue samples.  KNA samples from 
diverse tissues derived from nontransgenic mice contain very 
little mouse K mKNA (29) indicating levels of lymphocyte 
contamination  that  are too low to account for the levels of 
human )x expression seen in these transgenic mice (29). Fur- 
ther, all the X transgenic strains display similar tissue expres- 
sion patterns,  suggesting that such widespread expression is 
not an idiosyncrasy of the site of insertion of the transgene 
(29). Although an instance of Ig H chain transgene transcrip- 
tion  in  the brain  has been reported  (4),  such expression is 
generally limited to the lymphoid system (30-32).  One in- 
terpretation of these results would be that the transgene used 
in these studies lacks putative negative regulatory elements 
normally encoded in the vicinity of rearranged  ~, L chain genes. 
It may be necessary to exclude these sequences to gain  ex- 
pression  of this  gene in  nonlymphoid  tissues. 
Susceptibility to Infectious Disease.  Hemizygous carriers of 
the fusion transgene in one of the ~, strains  (EG) displayed 
a striking phenotype involving susceptibility to infectious dis- 
ease.  The average life expectancy of this strain in an animal 
colony containing several endemic pathogens was 90 d, whereas 
wild-type FVB/N mice (held for cancer incidence studies) 
frequently live for 2 yr in this environment.  Deaths in the 
EG strain  were largely due to  acute pneumonia  caused by 
a combination of Sendai virus and bacterial or mycoplasma 
Figure 1.  (A) Diagram of the DNA construct used to generate Jk trans- 
genics. (B) KNase protection analysis of human )~ transcription in B-less 
ttansgenic mice. 10-#g samples of RNA were hybridized to a uniformly 
labeled RNA  probe complementary to  the  variable  region of U266)x 
mRNA, digested with RNase, and electrophoresed  on a 5% sequencing 
gel. The negative control is wild-type spleen  (wt.  spleen).  (Bottom)  Un- 
digested probe, 783 nucleotide. Direction of migration is to the right. 344- 
nucleotide protected VS fragment is indicated by (?). 
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Figure 2.  Flow cytometric analysis of B cells in bone marrow 
and spleen of wild-type and X transgenic mice. (A) and (B) Ly-5 
(B220) staining of bone marrow and spleen cells. (C) and (D) mouse 
r  and #  staining of spleen cells. See Table 1 for percent antigen- 
positive cells. Cells were labeled with the rat anti-mouse B220 an- 
tibody (6B2) and FITC-conjugated goat anti-rat antibody, or with 
FITC-conjugated rat anti-mouse r (MRCox-20) or goat anti-mouse 
#. Control cells received only goat anti-rat antibody (A and B) 
or no antibody (C and D). GAR-IG, goat anti-rat Ig. 
infections. Often there was evidence of hepatic necrosis and 
central nervous system demyelination, indicative of mouse 
hepatitis virus infection. In contrast, hemizygous EG/+ mice 
raised under specific pathogen-free (SPF) conditions display 
none of these pathologies and live nearly normal life spans. 
Notwithstanding the widespread expression of the transgene, 
all other organ systems (except the B cell compartments re- 
ferred to below) of the pathogen-free EG mice appeared to 
be normal. Given this susceptibility to infectious disease, SPF 
EG/+  mice were used in the studies that follow. Further- 
more, although the mice characterized below were generally 
4-10 wk old, similar results were obtained with mice ranging 
from 3 wk to 2 yr of age. 
Immunodeficiency in EG Transgenics.  The pronounced sen- 
sitivity to infectious disease of the hemizygous EG animals 
suggested an immunodeficiency  state. Accordingly, we evalu- 
ated the immune system in that strain in comparison with 
wild-type littermates. In addition to the EG mice, another 
of our X transgenic lines (ET) has a reduced B cell popula- 
tion (see below). However, none of our other X transgenic 
mice (nor other Ig transgenics reported to date [3]) are un- 
usually susceptible to infection, nor do they display the se- 
vere immunodeficiency phenotype seen in  the EG  strain. 
Spleens of mature EG/+  mice are morphologically normal, 
but they are 50-75%  smaller than normal, containing 1-5 
x  107 cells  as compared with 0.8-1.2  x  10  s cells in the 
spleens  of their wild-type littermates. 
The gross findings were confirmed at the cellular level using 
flow cytometric analysis. Cells bearing the pre-B and B cell 
marker, B220 (LY5), were significantly reduced in EG bone 
marrow (27 vs. 6.5%)  and spleen (40 vs.  2.1%)  (see Table 
1) (24, 33, 34). The spleens of EG/+ mice contain 95% fewer 
B220 (Ly5) + cells than spleens from wild-type control mice 
(Table 1), while spleens from homozygous EG/EG mice dis- 
Table  1.  B  Cell Surface Antigen-positive  Cells in Lymphocytes 
from Spleen and Bone Marrow of Normal and B-less mice 
EG (FVB/N 
Tissue  wt (FVB/N)  EG (FVB/N)  x  C57BL/6) 
Table  2.  Serum lg (sis) in Bone Marrow  Chimeras 
Time post- 
Donor  Host  sIg  transplant 
mg/ml  d 
Spleen  wt  EG  1.0  +  0.27  60 
B220 (Ly5)  40  _+  7.1  (8)*  2.1  _+  0.97  (14)  11  _+  1.4 (2)  EG  wt  0.37  _+  0.21  60 
Mouse  r  37  _+  11  (11)  2.3  _+  2.0 (14)  7.4  _+  0.1  (2)  wt*  wt  2.0  _+  0.8  60 
Mouse /~  39  _+  11  (8)  1.6  +  0.93  (6)  13  _+  1.5 (2)  EG  wt  1.0  _+ 0.59  80 
wt*  EG  4.5  _+ 2.5  80  Bone marrow 
B220 (LyS) 27.2  _+ 2.4 (6)  6.5  _+  1.7 (6)  ND 
* Mean percentage  _+  SD (number tested). 
The mean and SD are shown. Each group contains either  five or six 
animals. Controls: wt, 4.2  _+  1.4 mg/ml; EG, 0.033  +  0.015 mg/ml. 
* Phenotypically normal line containing a lacZ transgene. 
Figure 3.  Immunohistochemical  analysis of frozen sections of spleens from wild-type (A, C and E) and B-less (B, D, and F) animals. Sections were 
stained with either no primary antibody (A and B), anti-B220 (C and D), or anti-Thy-l.1 (D and E) followed by biotinylated  goat anti-rat Ig and 
HRP avidin/biotin complex. Finally, the sections were incubated with AEC, which produced the red signal, and counterstained with hematoxylin. 
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Figure 4.  Flow cytometric analysis of thymic and splenic T cells in B-less and wild-type mice. Thymus cells stained for: (A) CD3 (2Cll),  (B) CD4 
(GK1.5), and (C) CD8 (Lyt-2), and (D) spleen cells labded with anti-CD4 antibody. 2Cll is an unconjugated hamster antibody and was labded with 
FITC-conjugated goat anti-hamster antiserum. The control in A received only the goat anti-hamster antiserum. CD4 and CD8 antibodies were directly 
conjugated and the controls in B, C, and D received no antibody. The difference in the CD3 staining of EG and wild-type thymus cells is probably 
not significant,  as we have not consistently observed this shift in other experiments.  (GAH-IG)Goat anti-hamster Ig. (GAR-IG)Goat anti-rat Ig. 
play a >99% reduction in B cells (data not shown). Note 
that more mature B cells expressing surface Ig are also greatly 
reduced in the spleen (Fig.  2,  C  and D).  Consistent with 
this, serum Ig levels in EG/+  mice are also reduced to <1% 
of that of wild-type (see legend of Table 2), while the level 
of Ig is below the limit of detection in homozygous EG/EG 
animals  (data  not shown). 
To determine whether the splenic architecture of the affected 
transgenic mice is perturbed, we analyzed histological sec- 
tions of EG and wild-type spleens. Although the gross mor- 
phology of EG spleens appears normal, immunohistochem- 
ical  staining with  a  B  cell-specific  antibody  (anti-B220) 
dramatically illustrates the extent of the B cell deficiency (Fig. 
3, C and D). The reddish-brown stain marks the B cells that 
extensively populate the white pulp surrounding the central 
arterioles  of the normal spleen (Fig. 3 C) (see reference 35 
for a review of spleen structure). In contrast, EG spleens con- 
tain only small clusters of B220 + cells at the margin of the 
white pulp (Fig. 3 D). However, the remainder of the white 
pulp stains strongly with the T  cell marker thy-1 (Fig.  3, 
E  and F).  A  similar picture emerges when spleen sections 
are  stained with anti-mouse IgM (not  shown). Controls 
treated with secondary antibody alone display no staining 
(Fig. 3, A and B; also see Fig. 2 B). As shown below, there 
is no human X protein on the surface of EG splenocytes (Fig. 
6 B), and flow cytometry reveals a large, unusual population 
of EG splenocytes bearing the Sca-1 antigen (described below, 
see Fig.  9 A). 
The Defect Appears Restricted to the B  Cell Lineage.  We 
used flow cytometric analysis to assess the T cell population 
in hemizygous EG transgenic mice. Fig. 4, A-D illustrates 
that the thymic and splenic T cell populations are indistin- 
guishable from those of wild-type mice with respect to cells 
bearing the CD3, CD4, and CD8 antigen markers (the some- 
what larger numbers of CD3 + cells in the EG thymus (Fig. 
4 A) is not normally seen and may reflect an infectious state 
in that particular animal). To confirm the lack of functional 
B cells, and to determine whether the T cell compartment 
is functional, we performed mitogen stimulation assays on 
spleen cells. Stimulation of splenic lymphocytes with the B 
cell specific mitogen, LPS, indicates that there are few, if any, 
functional B cells in EG spleens (Fig. 5 A). However,  Con 
A, a T cell-specific mitogen, induces a T cell response com- 
parable with that of wild-type (Fig. 5 B), indicating that the 
T  cell component is  relatively  intact.  Thus the effect  of 
the EG transgene appears to spare T cells while eliminating 
the B cells. The severe, specific pre-B  and B cell deficiency 
in the EG transgenic strain has led us to call this mutation 
"B-less" 
Human A Protein Is Present in B-less Mice.  The presence 
of human X mRNA is not per sea measure of human ~, L 
chain. To determine whether the transgenic human X mlLNA 
is translated,  we performed sandwich immunosorbant assays 
to detect mouse and human Ig in B-less sera. Samples were 
found to contain 0.3-6.0 mg/ml of human X protein, although 
H chain concentrations are <0.02 mg/ml (the limit of detec- 
tion in this assay). Thus, X chains in B-less serum are present 
primarily as free L chains. To determine whether the partic- 
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Figure 5.  Mitogen stimulation  of wild-type and B-less  (EG) splenocytes. 
(A) LPS and (B) Con A. Tritium uptake is indicated in cpm (xl0 -2 in 
A and  xlO  -3 in/3) incorporated per 104 cells. Control samples received 
cuhure medium with no specific mitogen. Each bar represents a single 
culture. 
Figure 6.  Flow cytometric analysis  of cells  labeled with anti-hu-)~ mAb. 
(A) A tumor cell line, EG/E#-c-myc-EB10298, which arose in a mouse 
bearing both the ~ and the E#-myc transgenes. (/3) Wild-type and B-less 
splenocytes labeled with anti-hu-~, antibody. Human X proteins are not 
present on the surface of splenocytes from B-less mice and the anti-hu-X 
mAb does not cross-react with mouse K. The hu-X (HU-LAMBDA), m-g 
(KAPPA),  and m-/~ (MU) antibodies are all directly conjugated with FITC, 
and the controls  received no antibody. 
ular human  X L chain encoded by the transgene  is capable 
of forming stable complexes with mouse H  chains, we ana- 
lyzed a cell line that  expresses both the mouse #  H  chain, 
and the transgenic X L chain.  This line (EG/EB10298) was 
derived from a pre-B cell lymphoma  that  arose in  a trans- 
genic mouse bearing both  the human  X transgene  and  an 
oncogenic El~-c-myc transgene  (16).  This cell line expresses 
comparable quantities of/~ and X chains as measured in whole 
cell extracts (see Table 3) and mouse/~ and human X chains 
are present on its surface (Fig.  6 A). Similar results were ob- 
tained  using  three  other  X/El~-c-myc cell  lines  (data  not 
shown). As would be expected, the mouse/~ chain is immu- 
noprecipitated from whole cell extracts of these coexpressing 
tumors using an antibody directed against the human X chain 
(Fig. 7). Furthermore,  none of these tumors express mouse 
K  chains (and all retain both K alleles in the germline configu- 
ration,  see Table 3), suggesting that the human h-mouse/x 
complexes are functional to the extent that they mediate iso- 
type exclusion. 
Since there are so few B cells in B-less mice, it is not sur- 
prising that human X chains are not detectable on the surface 
of splenic lymphocytes (Fig.  6 B), despite the high level ex- 
pression of human X mRNA observed in B-less spleens.  Cell 
Table  3.  Ig Concentrations in  Whole Cell Extracts and Gene Rearrangements in A.MuLV transformed and Lymphoma Cell Lines 
Derived from Wild-Type and Transgenic Mice 
Mouse #  genes (D-J)  K genes 
Human  k  Mouse # 
TG  ng/mg  ng/ml  K/K*  R/G  G/G  G/G 
None  <20  (8)  23  •  13  (7)*  100%  (8)  0  0  100%  (8) 
EG  700  _+  1,100  (16)*  16  +_  10 (16)11  70%  (19)  19%  (5)  11%  (3)  100%  (27) 
EG/EBq  420 (1)  340 (1)  100%  (3)  0  0  100%  (3) 
Numbers in parentheses represent  number of cell lines tested. 
* R, rearranged;  G, germline, number of cell lines. 
t One line contained 2,370  ng/ml of #  protein. 
S One line contained 5,400  ng/ml of human X; two of these cell lines contained  no measurable human X protein despite the fact that they still 
contained the transgene. 
LI One of these lines contained 1,150 ng/ml of mouse/~ protein; two contained 34 and 48 ng/ml, and the rest contained no detectable mouse # protein. 
￿82  X/El~-c-myc tumor cell lines (see Materials and Methods). 
1175  Vasicek  et al. Figure 7.  SDS-PAGE  analysis of 
immunoprecipitated human ~, pro- 
tein from the X-EG/Em-myc  tumor 
cell line, EG/EB10298. Cells were 
labeled  with  [3sS]-methionine, 
lysed, and treated with anti-human 
antibodies. The positions of human 
X, mouse #, and size markers are 
indicated. 
surface expression depends  on  expression of an Ig H  chain 
which,  in turn,  occurs only in B  cells.  In another  ), trans- 
genic strain (ET) that produces appreciable numbers of B cells, 
50-60%  of the B220 +  splenic lymphocytes bear human 
and mouse #  chains, but no mouse r  chains (data not shown), 
again consistent with the functional integrity of the human 
~,  transgene. 
The B-less Defect Is Autonomous  to Cells of the B  Lineage. 
That  the B-less phenotype is a B  cell autonomous property 
was established using in vitro bone marrow cultures derived 
from transgenic and wild-type bone marrow stem cells and 
stromal feeder cells (17). We found that B-less bone marrow 
stroma supports the growth of feeder-dependent,  wild-type 
B  cells in culture up  to levels of 2  x  106 cells/ml,  and cul- 
tures  of B-less bone marrow  and  fetal liver cells  grown  on 
wild-type  feeder layers  generate  <10  s  cells/ml. 
To confirm that the B-less defect is intrinsic to B cells, we 
generated bone marrow chimeras by injecting irradiated B-less 
Figure 8.  Southern blot analysis of PBL DNA from bone marrow transplant animals 60 d posttransplant.  DNA was digested with BamHI. wt* 
animals were the TG.XA strain which is marked with a lacZ transgene. The blot was serially probed with human X, lacZ, and mouse c-rayc  probes. 
The sizes of the relevant DNA fragments are indicated. 
1176  B Cell-deficient Mice Expressing a Human )~ Transgene (EG) animals with wild-type bone marrow and B-less bone 
marrow into irradiated wild-type animals. To permit iden- 
tification of the wild-type donor cells in reconstituted chi- 
meric hosts, we used otherwise normal bone marrow donors 
bearing a lacZ transgene as a genetic marker (designated wt*, 
Fig. 8). Control, wild-type, and B.less host mice do not con- 
tain lacZ crosshybridizing DNA, which can only be provided 
by the transplant (Fig. 8, controls lanes). PBLs from five wild- 
type mice reconstituted with wt* bone marrow are marked 
with  the  lacZ  gene  (Fig.  8,  wt*-,.wt  lanes)  and  thus  are 
chimeras  with  contributions  from  the  wt*  donor.  B-less 
recipients of wt* bone marrow also display the lacZ band 
(Fig. 8, wt*-~EG lanes). All mice reconstituted with normal 
bone marrow (including the B-less recipients) display normal 
serum Ig levels 60 d after transplantation (Table 2). Although 
hematopoietic cells from the B-less donor populate the pe- 
ripheral blood of the wild-type host mice reconstituted with 
B-less bone marrow,  these cells  (because  they lack  B  cell 
precursors) fail to reconstitute the serum Ig to wild-type levels 
within 60 d  (Table 2,  Fig.  8, EG--,'wt* lanes).  The appar- 
ently normal levels of serum Ig seen 80 d post-transplant (Table 
2) are likely to be due to host B cell recovery. Evidence of 
such minimal host B cell recovery is visible in the wt*  to 
EG  graft  (see  the faint human ~  band in wt*---~EG lanes 
[Fig. 8]). 
A-MuLV Transformation  Indicates a Profound  Deficiency of  Pre-B 
Cells.  To determine the level at which B cell development 
is blocked in B-less mice, we used the A-MuLV transforma- 
tion assay to quantitate early B cell precursors in B-less bone 
marrow and fetal liver. A-MuLV specifically transforms B cell 
precursors in these organs (18) and can be used to assess the 
number of pre-B cell targets in these populations. Transfor- 
mation of B-less bone marrow and day 14-17 fetal liver yielded 
<2%  of the normal number of transformed colonies, sug- 
gesting that the block in B cell development occurs very early 
in the B lineage pathway. For example, day 16 embryos from 
wild-type mice yielded 170 (+  100, n =  9) transformed colo- 
nies per 106 fetal liver cells, and B-less embryos yielded only 
3.0 (+_  2.7,  n  --  7). 
To further characterize the rare A-MuLV-transformed clones 
that arise from infection orB-less fetal liver cells, several trans- 
formed cells were cultured, the arrangements of their Ig genes 
were determined, and their Ig protein production was as- 
sayed (Table 3). Although the rare transformed cells obtained 
from B-less fetal liver are apparently B cell precursors by these 
criteria, they are distinct from those obtained from wild-type 
animals. When assessed  after 3 mo in culture, 30%  of the 
B-less-derived  cell lines retain one or both H  chain alleles in 
the germline configuration,  while the wild-type cell lines 
generally rearrange both their H  chain alleles.  Further,  14 
of 16 transformed B-less cell lines express large quantities of 
human X protein, while only three express mouse/~ chains 
(Table 3).  All the transformed lines retained their K genes 
in the germline configuration. 
Appearance of  Sca-l-bearing Cells among B-less  Splenoc~tes.  To 
determine whether B cell precursors are altered in B-less mice, 
we examined cells for the expression of several antigens char- 
acteristic of hematopoietic progenitors. Among those tested, 
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Figure  9.  Flow cytometric analysis of Sca-1 on spleen and bone marrow 
cells labeled with antibody to Sca-1. (A) Spleen and (B) bone marrow cells. 
FITC-conjugated goat anti-rat antiserum (GAR.IG) was used as the second 
antibody to label the Sca-1 Ab. 
a dramatic difference is detectable with an antibody to the 
Ly-6A.2 antigen (the stem cell antigen-1 [Sca-1]). The labeling 
profile of B-less splenocytes with the Sca-1 antibody reveals 
a relatively increased population of strongly positive cells (Fig. 
9 A),  though such cells are not seen in the bone marrow 
(Fig.  9, A  and B, Table 4).  Other antigens, such as AA4, 
BP1,  and Mac1,  showed no differences. 
The significance of the appearance of cells bearing this an- 
tigen is not clear.  Certain T  cells and endothelial cells nor- 
mally express Sca-1 antigen at low levels, and a rare popula- 
tion of bone marrow cells ("0.01%)  express high levels of 
this antigen and represent pluripotent hematopoietic progen- 
itor cells (36). Since hematopoietic progenitors are not nor- 
mally found in the spleens of healthy adult mice, T cells and 
endothelial cells constitute the Sca-1 + population normally 
found in the peripheral lymphoid organs. A portion of the 
Sca-1 + population we observe may include B cell precursors 
(or other hematopoietic precursors). Alternatively, they may 
represent a cell type induced to hyperproliferation in response 
Table  4.  Sca-1 + Cells in Spleen and Bone Marrow 
Tissue  wt*  EG* 
Spleen 
Sca-I (Ly-6)  9.8  •  6.4 (3)  40.1  •  10.2 (4) 
Bone marrow 
Sca-I (Ly-6)  1.4 (1)  1.2 (1) 
" Mean  percentage  +  SD (no.  tested). to the B cell deficiency, perhaps because of the action of a 
lymphokine. Alternatively, they may be bone marrow cells 
induced to migrate to the periphery because of the deficiency. 
As a rough test of this precursor notion, we determined that 
B-less splenocytes produce 5-10-fold more spleen colonies (mea- 
sured 12 d posttransplant) than do wild-type splenocytes when 
injected into lethally irradiated wild-type recipients (CFU-S 
assay, data not shown). 
The B-less Phenotype Is Suppressed on the C57BL/FVB Hy- 
brid Background.  In the course of experiments designed to 
determine whether humoral immunity plays a role in tissue 
graft  rejection,  we  generated Fl  mice bearing  the B-less 
transgene on the hybrid background C57BL/6  x  FVB/N. 
By comparison to mice carrying the transgene in the FVB/N 
background, these mice displayed a less dramatic reduction 
in B cell number ('-25%  of the normal level) with surface 
Ig levels that were only one-third to one-fourth normal (Table 
1).  In addition,  these mice were quite healthy, displaying 
no increased susceptibility to infection. The fact that hybrid 
(C57BL/6  x  FBV/N)F1 transgene carriers are less severely 
affected than the inbred FVB/N mice suggests the presence 
of a dominant suppressor(s) in the C57BL/6  genome. 
The Possible Basis of the B Lineage Defect.  We have shown 
that the immunodeficiency syndrome we observe is cell au- 
tonomous. That is, B-less bone marrow is not capable of es- 
tablishing B cell cultures on wild-type stromal feeder layers 
in tissue culture. Further, wild-type bone marrow is capable 
of reconstituting lethally irradiated B-less mice with normal 
(donor type) B cells and normal levels of serum Ig (Fig.  8, 
and Table 2).  It is thus likely that certain classes of B cell 
progenitors  are deficient in B-less mice.  The reduction in 
B220 § cells in the bone marrow is consistent with this in- 
terpretation. It is also (though not exclusively) consistent with 
the finding that the A-MuLV target cell population is reduced 
to <2% of that of wild-type levels, a finding strongly sug- 
gestive of the absence of pre-B cells. 
The B-less transgene has a dramatic effect on B cell popula- 
tions in  hemizygotls EG/+  mice,  suggesting a dominant 
genetic function. At least two models can be invoked to ex- 
plain these results. In a relatively indirect model, the EG trans- 
gene might create a loss-of-function mutation by virtue of 
its insertion into a gene both essential for B cell development 
and sensitive to gene dosage. If this model were correct, B-less 
mice should display a dosage-dependent phenotype. As we 
have noted, homozygous animals do indeed have a more se- 
vere phenotype than hemizygotes. Nevertheless, the possi- 
bility that this phenotype is brought about by the insertional 
mutation of an endogenous gene is unlikely since we have 
produced an additional transgenic mouse strain bearing the 
same transgene construct which develops a similar,  though 
less severe, B cell deficiency. Since the common element be- 
tween these strains is the transgene, and is not likely to be 
the site of its insertion, the insertional mutagenesis model 
becomes far less likely. 
Alternatively, a second model holds that expression of the 
human X transgene is itself detrimental to B cell develop- 
ment, again in a dose-dependent manner. Variation in ex- 
pression may be due to gene dosage or the spacial and/or 
temporal  profile  of  transgene  expression  which  may be 
influenced by copy number or the insertion site environment. 
Furthermore, U266X may be functionally distinct from other 
Ig transgenes in its ability to interfere with B cell develop- 
ment. The observation that previously reported Ig transgenics 
display some reduction in B cell populations (3) and that an- 
other of our X transgenic mice displays a phenotype similar 
to that of B-less is most consistent with this model. If this 
is correct, we must consider more detailed mechanisms by 
which aberrant expression of H  or L chains could alter B 
cell development. 
One such mechanism could depend upon allelic exclusion 
that normally regulates B cell development by preventing the 
expression of multiple idiotypes in any single B cell.  Since 
antibody production and expression play a role in inducing 
expansion of cells of the B lineage, impairing expression of 
the endogenous antibody repertoire could interfere with this 
process. This mechanism would require expression of the in- 
terfering Ig transgene in early B cell precursors to foreclose 
expansion of the immune repertoire. 
Another possible mechanism is suggested by the fact that 
the B-less phenotype eliminates cells of early B lineage. The 
prematurely expressed X chain (or perhaps specifically  the 
human U266X chain) might interact with a cellular compo- 
nent(s) needed for very early B cell development. Such a cel- 
lular component might include one of the X-like proteins 
(such as VpreB or CO [XS] [37-39]) essential for intracellular 
Ig traffic.  This dominant-negative mechanism is consistent 
with the fact that the human X L chain transgene is expressed 
in a variety of tissues,  but is deleterious only in the B cell 
lineage. We can only speculate that the more severe effect 
seen in the B-less strain is due to either a higher level of X 
expression in precursor cells and/or expression at an earlier 
time of B cell development than in those strains which fail 
to show the full phenotype. Such variation in expression, if 
it occurs, could be a consequence of the site of integration 
of the transgene. 
Significance and Use orB-less Mice.  B-less  mice display a 
B cell deficiency that is similar in some respects to that ob- 
served in X-linked agammaglobulinemia (XLA) in humans 
(10). A notable difference is that bone marrow derived from 
patients with XLA contains normal numbers of pre-B cells. 
Both diseases result in virtually complete absence of mature, 
functional B cells. Thus, in addition to complementing the 
available murine immunodeficiency  models, the B-less mouse 
provides a model system for the study of the importance of 
B cells in antigen presentation and T  cell maturation (40, 
41). It is particularly interesting to speculate on which other 
cells may substitute for B cells in the context of B cell im- 
munodeficiencies (I1). The B-less mouse should also provide 
insight into earlier stages of B cell development, and its study 
should illuminate the functions of B cells in cell-mediated 
immunity. Furthermore, the amplification of a novel cell popu- 
lation (Sca-l+) suggests that the absence of B cells in B-less 
transgenic mice may stimulate proliferation of other novel 
cell types, perhaps under the influence of aberrantly produced 
growth factors for which the B-less mouse may ultimately 
provide a convenient source. 
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